Evidence map›Paper›PMID 36002781›Full record

ArticleMolecular neurobiology2022

Antagonism of the Muscarinic Acetylcholine Type 1 Receptor Enhances Mitochondrial Membrane Potential and Expression of Respiratory Chain Components via AMPK in Human Neuroblastoma SH-SY5Y Cells and Primary Neurons.

Farhana Naznin, T M Zaved Waise, Paul Fernyhough

Open access · hybridAbstract read
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Farhana NazninDivision of Neurodegenerative Disorders, St Boniface Hospital Albrechtsen Research Centre, R4046 - 351 Taché Ave, Winnipeg, MB, R2H 2A6, Canada.
T M Zaved WaiseDivision of Neurodegenerative Disorders, St Boniface Hospital Albrechtsen Research Centre, R4046 - 351 Taché Ave, Winnipeg, MB, R2H 2A6, Canada.
Paul FernyhoughDivision of Neurodegenerative Disorders, St Boniface Hospital Albrechtsen Research Centre, R4046 - 351 Taché Ave, Winnipeg, MB, R2H 2A6, Canada. pfernyhough@sbrc.ca.ORCID http://orcid.org/0000-0002-9507-1201
St. Boniface Hospital · CA

Funding

Institute of Neurosciences, Mental Health and Addiction PJT-162172
6 · The paper itself

Abstract

Impairments in mitochondrial physiology play a role in the progression of multiple neurodegenerative conditions, including peripheral neuropathy in diabetes. Blockade of muscarinic acetylcholine type 1 receptor (M

Indexed as

NeuroblastomaPeripheral Nervous System DiseasesAcetylcholineAMP-Activated Protein KinasesElectron TransportFluorescent DyesHumansMembrane Potential, MitochondrialMitochondrial ProteinsMuscarinic AntagonistsNeuronsPirenzepineReceptors, MuscarinicRNA, Small InterferingAcetylcholineAMP-Activated Protein KinasesFluorescent DyesMitochondrial ProteinsMuscarinic AntagonistsPirenzepineReceptors, MuscarinicRNA, Small InterferingAxonDiabetic neuropathyDorsal root gangliaMitochondriaOXPHOSPlasma membrane potential

Identifiers

PMID36002781
PMCPMC9525428
OpenAlexW4293105417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.